Dr Subas Sakya, Chief Scientific Officer at BioDuro
BioDuro, a trusted global Contract Research, Development, and Manufacturing Organisation, has announced a groundbreaking partnership with Silicogenix, the pioneer of fit-for-purpose small molecule design technology that empowers polypharmacology and non-traditional drug development. The collaboration combines BioDuro’s leading drug discovery platform with SGX’s novel frameworks to lower the cost and time barriers in developing complex therapies.
‘We are focused on the continued innovation of our fully integrated services to help meet growing demand for early drug discovery,’ said Dr Subas Sakya, Chief Scientific Officer at BioDuro. ‘We are excited to partner with SGX to enable an alternative path for new drug discovery, propelling first-in-class therapeutics with the potential to save lives.’
SGX’s technology enables biopharma companies to rapidly initiate and test new therapies, including possible combinations with standard-of-care treatments, due to their ability to access the majority of the human proteome. Leveraging the leading drug discovery platform, BioDuro delivers various complex molecules at speed, and accelerating the path from drug discovery through to preclinical at a lower cost.
About BioDuro
BioDuro, an Advent International portfolio company, is a CRDMO with a 29-year proven track record. Headquartered in Irvine, California, USA, our global presence spans seven sites across the United States and China, and over 2,000 employees. Specializing in both small and large molecule discovery, development, scale-up, and manufacturing, we offer fully integrated services from early drug discovery to commercial manufacturing across chemistry, biology, drug metabolism and pharmacokinetics (DMPK), drug substance, and drug product. For more information, please visit www.bioduro.com.
About Silicogenix
Silicogenix (SGX) is pioneering fit-for-purpose small molecule design technology that empowers polypharmacology and non-traditional drug development for cancers and complex diseases. Backed by nearly 100 years of combined experience in pharma and AI, SGX’s proprietary, ultra-fast, and high-throughput frameworks enable novel approaches to drug discovery that have been inaccessible to experimental methods. By leveraging both target and molecule diversity, SGX is lowering barriers to developing modern, first-in-class oncology and immunology therapeutics that can comprehensively address diseases and save lives. For more information, visit www.silicogenix.com.
